{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:27Z","timestamp":1787026527304,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study investigates the impact of transvascular antitumor interventional therapies on immune cell dynamics and its correlation with disease control and progression-free survival (PFS) in hepatocellular carcinoma (HCC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center observational case-control study was conducted with 119 HCC patients. Transvascular antitumor interventional therapy were administered based on patient-specific evaluations. Peripheral blood samples were collected before and within 28 days after the first treatment to analyze lymphocyte subsets and other immune cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher counts of total white blood cells (WBCs), lymphocytes, monocytes, and basophils were significantly associated with disease control rate. Subgroup analysis revealed that abnormal BMI, diabetes, infection, and multiple lesions were significantly associated with T cell abnormalities. Age, abnormal BMI, hypertension, and abnormal AFP were linked to total T cell abnormalities. NK cells, B cells, Th cells, Tc\/Ts cells, and CD4\/CD8 ratios did not show significant differences in PFS probabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher counts of WBCs, lymphocytes, monocytes, and basophils, play a crucial role in the effectiveness of HCC interventional therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1450525","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:26:59Z","timestamp":1728347219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuan-Dong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Xiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000514194","article-title":"Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF liver 100 trial","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.09.019","article-title":"Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma","volume":"12","author":"Du","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00378-2","article-title":"Hypoxia-associated circPRDM4 promotes immune escape via HIF-1\u03b1 regulation of PD-L1 in hepatocellular carcinoma","volume":"12","author":"Chen","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00350-4","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2022","journal-title":"biomark Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00275-0","article-title":"Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model","volume":"11","author":"Liu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01185-9","article-title":"Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization","volume":"20","author":"Chen","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020200201","article-title":"NRF2 dysregulation in hepatocellular carcinoma and ischemia: A cohort study and laboratory investigation","volume":"297","author":"Ziv","year":"2020","journal-title":"Radiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000513706","article-title":"Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein","volume":"10","author":"Kosaka","year":"2021","journal-title":"Liver Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S257934","article-title":"The prognostic value of inflammation factors in hepatocellular carcinoma patients with hepatic artery interventional treatments: A retrospective study","volume":"12","author":"Guo","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08253-1","article-title":"Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis","volume":"21","author":"Lu","year":"2021","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102659","article-title":"Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations","volume":"53","author":"Fujita","year":"2020","journal-title":"EBioMedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01024-y","article-title":"Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma","volume":"11","author":"Zhong","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01024-y","article-title":"A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape","volume":"14","author":"Long","year":"2022","journal-title":"Genome Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02439-6","article-title":"Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review","volume":"41","author":"Zhang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102622","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22300-2","article-title":"Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling","volume":"12","author":"Hu","year":"2021","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-023-00246-z","article-title":"Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment","volume":"11","author":"Tian","year":"2023","journal-title":"Bone Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000233","article-title":"Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein","volume":"8","author":"Torres","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.657051","article-title":"Identification and validation of an immune-related eRNA prognostic signature for hepatocellular carcinoma","volume":"12","author":"Cai","year":"2021","journal-title":"Front Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34543-z","article-title":"Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation","volume":"8","author":"Chu","year":"2018","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S373631","article-title":"Establishment of nomogram model for minimally invasive treatment of small hepatocellular carcinoma based on CD8(+)T cell counts","volume":"15","author":"Pu","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3533714","article-title":"Prognostic and clinical significance of aspartate aminotransferase-to-lymphocyte ratio index in individuals with liver cancer: A meta-analysis","volume":"2022","author":"Peng","year":"2022","journal-title":"Dis Markers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1057560","article-title":"Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000523849","article-title":"Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: A real-world, multicenter, retrospective study","volume":"11","author":"Xia","year":"2022","journal-title":"Liver Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin liver Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244293","article-title":"Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib","volume":"15","author":"Hsieh","year":"2020","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","article-title":"Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma","volume":"12","author":"Ho","year":"2021","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2023.01275","article-title":"The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy","volume":"17","author":"Duan","year":"2024","journal-title":"Bioscience Trends"},{"key":"B29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","article-title":"Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1433501","article-title":"A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE","volume":"19","author":"Zhang","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S358658","article-title":"Safety and efficacy of transarterial chemoembolization and immune checkpoint inhibition with camrelizumab for treatment of unresectable hepatocellular carcinoma","volume":"9","author":"Zhang","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03227-6","article-title":"Monocyte-derived S1P in the lymph node regulates immune responses","volume":"592","author":"Baeyens","year":"2021","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.08.013","article-title":"Secreted igD amplifies humoral T helper 2 cell responses by binding basophils via galectin-9 and CD44","volume":"49","author":"Shan","year":"2018","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.013","article-title":"Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27113545","article-title":"Targeted therapy of B7 family checkpoints as an innovative approach to overcome cancer therapy resistance: A review from chemotherapy to immunotherapy","volume":"27","author":"Taghavi","year":"2022","journal-title":"Molecules"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325288","article-title":"The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma","volume":"71","author":"Heinrich","year":"2022","journal-title":"Gut"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207074","article-title":"Effects of 3-HAA on HCC by regulating the heterogeneous macrophages-A scRNA-seq analysis","volume":"10","author":"Xue","year":"2023","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1450525\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:27:01Z","timestamp":1728347221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1450525\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2024.1450525"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1450525","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"article-number":"1450525"}}